Lunit, a global leader in AI-driven cancer diagnostics and biomarkers for oncology therapeutics, has entered into a strategic partnership with CellCarta, a leading provider of CRO laboratory services for pharmaceutical research and development. Through this collaboration, Lunit’s advanced AI pathology solutions will be integrated into CellCarta’s clinical trial services worldwide, enabling pharmaceutical sponsors to seamlessly adopt AI-powered analysis within established trial workflows.
With CAP-accredited and CLIA-certified laboratories across North America, Europe, and Asia, CellCarta is recognized for its expertise in pathology, biomarker development, and clinical trial support in oncology and immunology. The company has contributed to more than 1,000 clinical studies, including 75 Phase III PMA trials, developed over 250 unique IHC assays, and performs over 100,000 IHC stainings annually.
The partnership will expand global access to the Lunit SCOPE® suite, the company’s AI-powered digital pathology solution, designed to accelerate insights into tumor biology through analysis of H&E and IHC whole slide images. These insights can support biomarker development, identify patients most likely to benefit from targeted therapies, and advance both precision oncology and next-generation drug development.
Both companies bring complementary expertise in immune phenotype analysis. CellCarta contributes its capabilities in IHC stains such as panCK and CD8, while Lunit delivers AI-based H&E analysis through its Lunit SCOPE IO® product. Together, this collaboration will provide clinical trial sponsors access to quantitative immune phenotyping within CellCarta’s global infrastructure, including Lunit’s solution for quantifying tumor-infiltrating lymphocytes and classifying immune phenotypes.
Also Read: INBRAIN Neuroelectronics partners with Mayo Clinic to advance graphene BCI tech
The Lunit SCOPE suite which includes SCOPE IO, SCOPE PD-L1, and SCOPE uIHC has already been utilized by several major pharmaceutical companies in research to support biomarker-driven development and enhance patient selection strategies in oncology trials.
“As more biopharma companies turn to AI-powered pathology to streamline biomarker development and patient selection, the demand for scalable, clinically validated solutions is rapidly growing,” said Yannick Waumans, Director of Digital Pathology Solutions at CellCarta. “Partnering with Lunit allows us to offer our clients a powerful and proven AI platform that integrates seamlessly into global clinical trial workflows.”
“We’re thrilled to partner with CellCarta, a trusted CRO with a strong global presence and impressive leadership in digital pathology real-world deployment,” said Brandon Suh, CEO of Lunit. “This collaboration gives more clinical research teams a way to harness the power of AI in pathology, and we look forward to seeing its impact on trials and, ultimately, on patients.”
Earlier this year, at a workshop hosted at CellCarta’s Antwerp facility, Lunit showcased how its AI-powered pathology platform supports drug development through deep learning analysis of H&E and IHC images. The session highlighted real-world applications including tumor microenvironment profiling, genomic mutation prediction, and biomarker quantification across diverse cancer types.